(Reuters) – Eisai Co Ltd and Biogen Inc said on Thursday the European Medicines Agency (EMA) had accepted a marketing authorization application for their Alzheimer’s disease drug for review.
The drug, lecanemab, was recently granted accelerated approval in the United States.
(Reporting by Sriparna Roy in Bengaluru; Editing by Subhranshu Sahu)
